logo

Sangamo Biosciences Inc (SGMO)



Trade SGMO now with
  Date
  Headline
5/8/2019 4:03:07 PM Sangamo Therapeutics Q1 Loss/share $0.41 Vs. Loss $0.23 Year Ago
4/4/2019 8:05:04 AM Sangamo Therapeutics Prices Public Offering Of 11 Mln Shares At $11.50 Per Share
4/3/2019 4:02:45 PM Sangamo Therapeutics Announces Proposed Public Offering Of Common Stock
4/2/2019 7:05:59 AM Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
4/2/2019 7:01:56 AM Sangamo, Pfizer Announce Interim Data From Phase 1/2 Alta Study On SB-525 Gene Therapy For Severe Hemophilia A
3/29/2019 7:08:54 AM Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression
3/8/2019 5:03:26 AM Sangamo Reports Publication Of Data Showing New Zinc Finger Nuclease Architectures Enabling Genome Editing
2/20/2019 7:36:03 AM Sangamo Reports FDA Accepted Investigational New Drug Application For ST-920
1/22/2019 4:06:52 PM Sangamo Therapeutics Appoints Adrian Woolfson As EVP Of Research And Development
12/17/2018 8:12:39 AM Sangamo Announces Treatment Of The First Patient In Phase 1/2 Clinical Trial Evaluating SB-FIX
12/3/2018 7:12:58 AM Sangamo Therapeutics Completes Acquisition Of TxCell
10/1/2018 8:12:02 AM Sangamo And TxCell Announce Completion Of Acquisition By Sangamo Of Majority Of TxCell Ordinary Shares
9/5/2018 8:16:52 AM Sangamo Announces 16 Week Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913
7/23/2018 7:04:35 AM Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of SB-318 For MPS I